In this study, we assess the effectiveness of the PROTAC, SJF-0628, in the broader cellular background of heterozygous BRAF V600E-driven CRC and triple-negative breast cancer (TNBC) cell lines [11,40]. This evidence concerns the gene BRAF and triple-negative breast carcinoma.